Adicet Bio
The role involves coordinating and executing in vivo and ex vivo nonclinical studies to evaluate immune-cell and gene-therapy platforms, including efficacy, PK/PD, and safety assessments in murine models. The scientist will collaborate with cross‑functional teams and CROs, manage study design and timelines, and maintain detailed experimental records.
Adicet Bio is a clinical-stage biotechnology company developing off-the-shelf, allogeneic gamma delta T cell therapies for cancer and autoimmune diseases. Their proprietary platform engineers Gamma Delta 1 CAR T cells to enable novel targeting, tissue homing, and improved drug exposure with the goal of delivering best-in-class, on‑demand cell therapies. Adicet advances a pipeline of engineered cell therapy candidates and provides regular clinical and investor updates from offices in Redwood City, Boston and Shanghai.
Press Release Service: Adicet Bio Reports Third Quarter 2025 Financial Results and Provides Business Updates
Nov 6, 2025
Adicet Bio (ACET) Projected to Post Quarterly Earnings on Thursday
1 week ago
Woodline takes 6.5% passive stake in Adicet Bio (ACET)
2 weeks ago
Headquarters
San Francisco, CA
Company Size
201-500 employees
Founded
2018
Industry
Technology
Glassdoor Rating
4.2 / 5
Sarah Johnson
Chief Executive Officer
Michael Chen
Chief Technology Officer
Emily Williams
VP of Engineering
David Rodriguez
VP of Product
Jessica Thompson
Chief Financial Officer
Andrew Park
VP of Sales
View leadership team, funding history,
and employee contacts for Adicet Bio.
90% above the average for this role
Adicet Bio Announces Positive Preliminary Data from ADI-001 Phase 1 Study in Patients with Lupus Nephritis (LN) and Systemic Lupus Erythematosus (SLE)
Oct 7, 2025